论文部分内容阅读
目的比较非小细胞肺癌3种化疗方案的成本、临床疗效和不良反应,运用方案药物经济学方法进行最小成本分析。方法收集115例住院化疗患者的住院费用、临床疗效和化疗不良反应情况,比较NP和GP方案、DP方案的药物经济学指标。结果各组临床疗效和药物不良反应发生率之间差异无统计学意义。通过最小成本分析和敏感度分析显示,NP组优于GP组和DP组;DP组用于治疗药物不良反应的药费高于GP组,DP组ΔADR药费/Δ不良反应发生率(ΔC/ΔE)的值显著高于GP组(P<0.05)。结论根据药物经济学评价,NP方案为最经济方案,GP方案优于DP方案。
Objective To compare the cost, clinical efficacy and adverse reactions of three kinds of chemotherapy regimens for non-small cell lung cancer (NSCLC) and to analyze the minimal cost using the program pharmacoeconomic method. Methods The hospitalization costs, clinical efficacy and adverse reactions of chemotherapy in 115 inpatients undergoing chemotherapy were collected. Pharmacoeconomic indexes of NP and GP regimens were compared. Results There was no significant difference between the clinical efficacy and the adverse drug reaction rate in each group. Minimal cost analysis and sensitivity analysis showed that NP group was superior to GP group and DP group, DP group was higher than GP group for medication adverse drug reaction, and DPAD group was significantly lower than that of GP group (ΔADR drug cost / Δ adverse reaction rate (ΔC / ΔE) was significantly higher than the GP group (P <0.05). Conclusion According to the pharmacoeconomic evaluation, the NP program is the most economical program, and the GP program is superior to the DP program.